HRP20160303T1 - Peptid koji je sposoban produljiti vrijeme polu-života pogodnih peptida u plazmi - Google Patents
Peptid koji je sposoban produljiti vrijeme polu-života pogodnih peptida u plazmi Download PDFInfo
- Publication number
- HRP20160303T1 HRP20160303T1 HRP20160303TT HRP20160303T HRP20160303T1 HR P20160303 T1 HRP20160303 T1 HR P20160303T1 HR P20160303T T HRP20160303T T HR P20160303TT HR P20160303 T HRP20160303 T HR P20160303T HR P20160303 T1 HRP20160303 T1 HR P20160303T1
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- seq
- amino acid
- acid sequence
- sequence shown
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/63—Motilins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (4)
1. Kimerni peptid, naznačen time, da sadržava aminokiselinski slijed prikazan u SEQ ID: 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 118, 119, 120, 121, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 139, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 154, 155, 156, 157 ili 158.
2. Kimerni peptid u skladu s patentnim zahtjevom 1, naznačen time, da se sastoji od aminokiselinskog slijeda prikazanog u SEQ ID: 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 118, 119, 120, 121 , 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 139, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151 , 154, 155, 156, 157 ili 158.
3. Farmaceutski pripravak, naznačen time, da je kimerni peptid u skladu s patentnim zahtjevom 1 ili 2 ili njegove farmaceutski prihvatljive soli, djelotvorni sastojak.
4. Farmaceutski pripravak u skladu s patentnim zahtjevom 3, za uporabu u liječenju bolesti, naznačen time, da
(A) kimerni peptid je peptid koji se sastoji od sekvence aminokiselina prikazanim u SEQ ID: 106, 107 ili 108, a bolest je bolest odabrana od akutne srčane insuficijencije, kronične srčane insuficijencije, obliterativnog arterioskleroze, ishemijske bolesti srca, hipertenzije, edema bolesti, infarkta, retinitisa, dijabetičke bubrežne bolesti, nefroskleroze i infarkta miokarda;
(B) kimerni peptid je peptid koji se sastoji od aminokiselinskog slijeda prikazanog u SEQ ID: 109, 110, 124, 125, 126, 127, 128, 129, 130, 157 ili 158, a bolest je bolest odabrana iz skupine koju čine atipična hondrodisplazija, restenoza nakon PTCA nakon koronarne stenoze arterija, plućna hipertenzija, obliterativne bolesti perifernih arterija, osteoartritis, reumatoidni artritis, plućna fibroza, fibroza jetre, fibroza bubrega, infarkt miokarda i miokarditis; ili
(C) kimerni peptid je peptid koji se sastoji od aminokiselinskog slijeda prikazanog u SEQ ID: 111, 112, 113, 114, 115, 116, 118, 119, 120, 121, 131, 132, 133, 134, 135, 136 , 139, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 154, 155, ili 156, a bolest je bolest odabrana iz skupine koju čine funkcionalna dispepsija, povratni ezofagitis, dijabetička paraliza pokretljivosti želuca , konstipacija tipa sindrom iritabilnog crijeva, kronični pseudoileus, postoperativni ileus, kronični gastritis i atrofični gastritis.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008136106 | 2008-05-23 | ||
| EP09750669.5A EP2277890B1 (en) | 2008-05-23 | 2009-05-22 | Peptide capable of extending half-life of peptide of interest in plasma |
| PCT/JP2009/059464 WO2009142307A1 (ja) | 2008-05-23 | 2009-05-22 | 目的ペプチドの血漿中半減期延長作用を有するペプチド |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160303T1 true HRP20160303T1 (hr) | 2016-04-22 |
Family
ID=41340233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160303TT HRP20160303T1 (hr) | 2008-05-23 | 2009-05-22 | Peptid koji je sposoban produljiti vrijeme polu-života pogodnih peptida u plazmi |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8551937B2 (hr) |
| EP (1) | EP2277890B1 (hr) |
| JP (1) | JP5524049B2 (hr) |
| KR (2) | KR20130018965A (hr) |
| CN (1) | CN101809029B (hr) |
| BR (1) | BRPI0904622A2 (hr) |
| CA (1) | CA2698582C (hr) |
| CY (1) | CY1117478T1 (hr) |
| DK (1) | DK2277890T3 (hr) |
| ES (1) | ES2566830T3 (hr) |
| HR (1) | HRP20160303T1 (hr) |
| HU (1) | HUE028539T2 (hr) |
| PL (1) | PL2277890T3 (hr) |
| PT (1) | PT2277890E (hr) |
| SI (1) | SI2277890T1 (hr) |
| WO (1) | WO2009142307A1 (hr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3404102T1 (sl) | 2004-04-21 | 2021-11-30 | Alexion Pharmaceuticals, Inc. | Konjugati za dodajanje kostem in njihova uporaba za ciljanje beljakovin na kosti |
| PT2432489T (pt) * | 2009-05-20 | 2016-12-07 | Biomarin Pharm Inc | Variantes do péptido natriurético de tipo c |
| WO2012088608A1 (en) | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
| EP2481751A1 (en) * | 2011-01-26 | 2012-08-01 | PharmaSurgics in Sweden AB | Human lactoferrin derived peptides |
| US20140072557A1 (en) | 2011-02-28 | 2014-03-13 | National Cerebral And Cardiovascular Center | Medicinal agent for suppressing malignant tumor metastasis |
| EP2745846A4 (en) | 2011-08-19 | 2015-03-18 | Nat Cerebral & Cardiovascular Ct | MEDICAMENT FOR PREVENTING THE ABSORPTION OF SPICY TUMORS WITH A COMBINATION OF NATRIURETIC PEPTIDE RECEPTOR GC-A AGONISTS AND GC-B AGONISTS |
| WO2013099376A1 (ja) * | 2011-12-26 | 2013-07-04 | 国立大学法人福井大学 | 体外受精における成熟卵子マーカー及びその使用 |
| EP2853273A4 (en) * | 2012-04-25 | 2016-01-13 | Daiichi Sankyo Co Ltd | PROMOTER FOR BONE REPAIR |
| CN104302177B (zh) | 2012-05-17 | 2019-05-28 | 延伸生物科学股份有限公司 | 用于改进的药物递送的载体 |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| TW201442721A (zh) | 2013-01-23 | 2014-11-16 | Daiichi Sankyo Co Ltd | 糖鏈修飾心房利尿鈉肽 |
| CA2940835A1 (en) * | 2014-02-27 | 2015-09-03 | Daiichi Sankyo Company, Limited | Medicine against growth failure induced by administration of steroid |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| JP6787894B2 (ja) | 2014-12-05 | 2020-11-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 組換えアルカリホスファターゼを用いた発作の処置 |
| EP3250227A2 (en) | 2015-01-28 | 2017-12-06 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| MX2018002121A (es) | 2015-08-17 | 2018-06-18 | Alexion Pharma Inc | Elaboracion de fosfatasas alcalinas. |
| JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定 |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| CN114874313A (zh) * | 2015-11-16 | 2022-08-09 | Ubi蛋白公司 | 用于延长蛋白质半衰期的方法 |
| US11311604B2 (en) * | 2016-01-08 | 2022-04-26 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low NPR-C binding |
| WO2017118698A1 (en) * | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN |
| MX2018011833A (es) | 2016-04-01 | 2019-02-13 | Alexion Pharma Inc | Tratamiento para la debilidad muscular con fosfatasas alcalinas. |
| WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| AU2017261216B2 (en) * | 2016-05-06 | 2023-08-03 | Immunoforge Co., Ltd. | ELP fusion proteins for controlled and sustained release |
| EP3464573A4 (en) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | EFFECTS OF METALS ON THE PRODUCTION OF ALKALINE PHOSPHATASES |
| JP7018933B2 (ja) | 2016-08-18 | 2022-02-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 気管気管支軟化症の治療方法 |
| EP3574913A4 (en) * | 2017-01-24 | 2020-07-22 | Daiichi Sankyo Company, Limited | SMALL SIZE THERAPEUTIC AGENT |
| WO2018175534A1 (en) * | 2017-03-22 | 2018-09-27 | Pharmain Corporation | Npra agonists, compositions, and uses thereof |
| EP3600383A4 (en) | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS |
| EP3773684A1 (en) | 2018-03-30 | 2021-02-17 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| EP4393502A2 (en) * | 2018-12-26 | 2024-07-03 | Skinmed Co., Ltd. | Acetylcholine receptor inhibitory peptides and uses thereof |
| EP3923906A1 (en) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
| CN119613549A (zh) | 2019-06-12 | 2025-03-14 | 诺华股份有限公司 | 利钠肽受体1抗体及使用方法 |
| EP4072579A4 (en) | 2019-12-09 | 2024-05-01 | Alexion Pharmaceuticals, Inc. | ALKALINE PHOSPHATASE POLYPEPTIDES AND METHODS OF USE THEREOF |
| JP2024506912A (ja) | 2021-02-12 | 2024-02-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼポリペプチド及びその使用方法 |
| WO2024072637A2 (en) | 2022-09-30 | 2024-04-04 | Extend Biosciences, Inc. | Long-acting parathyroid hormone |
| WO2024162772A1 (ko) * | 2023-02-01 | 2024-08-08 | 주식회사 에이티지씨 | 생체 내 지속성이 증가된 생리활성물질의 결합체 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3026354B2 (ja) * | 1990-09-27 | 2000-03-27 | 壽之 松尾 | ヒトｃｎｐ遺伝子及び前駆体蛋白 |
| US20060263382A1 (en) * | 1998-06-20 | 2006-11-23 | Richard Hotchkiss | Membrane-permeant peptide complexes for treatment of sepsis |
| WO2001007475A1 (en) | 1999-07-23 | 2001-02-01 | Kenji Kangawa | Novel peptides |
| CN101177455A (zh) * | 2001-08-30 | 2008-05-14 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| DE60238541D1 (de) | 2001-08-30 | 2011-01-20 | Biorexis Pharmaceutical Corp | Modifizierte transferrin-fusionsproteine |
| JPWO2007058359A1 (ja) * | 2005-11-21 | 2009-05-07 | 国立大学法人 宮崎大学 | グレリン及びその誘導体又はＧＨＳ−Ｒ１ａに作用する物質を有効成分とする皮膚修復促進治療剤 |
| EP1967201A4 (en) * | 2005-11-21 | 2009-09-30 | Univ Miyazaki | THERAPEUTIC AGENT FOR SKIN OR SKIN REGENERATING AGENT CONTAINING DESACYL-GHRELINE OR A DERIVATIVE THEREOF AS ACTIVE INGREDIENT |
| BRPI0715809A2 (pt) * | 2006-08-11 | 2014-11-25 | Univ Miyazaki | Agente terapêutico para a aceleração da restauração do nervo espinhal compreendendo grelina, seus derivados ou substâncias capazes de atuar sobre o ghs-r1a como ingrediente ativo. |
| KR20090060290A (ko) | 2006-08-11 | 2009-06-11 | 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 | 데스아실 그렐린 및 그 유도체를 유효성분으로 포함하는 척수 신경 수복 촉진 치료제 |
| US20100034194A1 (en) * | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
-
2009
- 2009-05-22 DK DK09750669.5T patent/DK2277890T3/en active
- 2009-05-22 WO PCT/JP2009/059464 patent/WO2009142307A1/ja not_active Ceased
- 2009-05-22 JP JP2010513074A patent/JP5524049B2/ja not_active Expired - Fee Related
- 2009-05-22 KR KR1020127034358A patent/KR20130018965A/ko not_active Ceased
- 2009-05-22 BR BRPI0904622A patent/BRPI0904622A2/pt not_active Application Discontinuation
- 2009-05-22 US US12/675,961 patent/US8551937B2/en not_active Expired - Fee Related
- 2009-05-22 KR KR1020107004795A patent/KR101350251B1/ko not_active Expired - Fee Related
- 2009-05-22 PT PT97506695T patent/PT2277890E/pt unknown
- 2009-05-22 CN CN200980100291.9A patent/CN101809029B/zh not_active Expired - Fee Related
- 2009-05-22 EP EP09750669.5A patent/EP2277890B1/en active Active
- 2009-05-22 SI SI200931387T patent/SI2277890T1/sl unknown
- 2009-05-22 PL PL09750669T patent/PL2277890T3/pl unknown
- 2009-05-22 CA CA2698582A patent/CA2698582C/en not_active Expired - Fee Related
- 2009-05-22 HR HRP20160303TT patent/HRP20160303T1/hr unknown
- 2009-05-22 ES ES09750669.5T patent/ES2566830T3/es active Active
- 2009-05-22 HU HUE09750669A patent/HUE028539T2/en unknown
-
2016
- 2016-03-22 CY CY20161100242T patent/CY1117478T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009142307A1 (ja) | 2009-11-26 |
| PT2277890E (pt) | 2016-03-31 |
| BRPI0904622A2 (pt) | 2016-06-21 |
| KR101350251B1 (ko) | 2014-01-14 |
| EP2277890A4 (en) | 2011-08-24 |
| ES2566830T3 (es) | 2016-04-15 |
| KR20100038236A (ko) | 2010-04-13 |
| CN101809029B (zh) | 2016-06-15 |
| JPWO2009142307A1 (ja) | 2011-09-29 |
| EP2277890A1 (en) | 2011-01-26 |
| KR20130018965A (ko) | 2013-02-25 |
| CA2698582A1 (en) | 2009-11-26 |
| DK2277890T3 (en) | 2016-02-08 |
| CN101809029A (zh) | 2010-08-18 |
| US8551937B2 (en) | 2013-10-08 |
| EP2277890B1 (en) | 2016-01-06 |
| PL2277890T3 (pl) | 2016-06-30 |
| CA2698582C (en) | 2016-09-13 |
| US20100305031A1 (en) | 2010-12-02 |
| JP5524049B2 (ja) | 2014-06-18 |
| CY1117478T1 (el) | 2017-04-26 |
| HUE028539T2 (en) | 2016-12-28 |
| SI2277890T1 (sl) | 2016-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160303T1 (hr) | Peptid koji je sposoban produljiti vrijeme polu-života pogodnih peptida u plazmi | |
| Shantharam et al. | Inhibition of protein glycation by urea and thiourea derivatives of glycine/proline conjugated benzisoxazole analogue–Synthesis and structure–activity studies | |
| HRP20220995T1 (hr) | Trostruki aktivator koji aktivira glukagonski, glp-1 i gip receptore | |
| RS54020B1 (en) | Boronate ester compounds and pharmaceutical compositions thereof | |
| MX2009006631A (es) | Imidazoles como inhibidores de sintasa de aldosterona. | |
| HRP20140691T1 (hr) | Supstituirani derivati karbamoilmetilamino octene kiseline kao novi nep-inhibitori | |
| TWI330176B (en) | Inhibitor against the production and secretion of amyloid protein | |
| WO2005082863A3 (en) | 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors | |
| PE20070717A1 (es) | Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida | |
| JP2010514715A5 (hr) | ||
| MX2011008952A (es) | Activadores de guanilato ciclasa solubles. | |
| JP2010180229A (ja) | スルホンアミド含有インドール化合物 | |
| Lee et al. | Caffeoylglycolic and caffeoylamino acid derivatives, halfmers of L-chicoric acid, as new HIV-1 integrase inhibitors | |
| MY160256A (en) | Novel indole compounds | |
| JP2016539089A5 (hr) | ||
| AR069554A1 (es) | Compuesto triciclico de amino benzoimidazol | |
| DK1716152T3 (da) | Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser | |
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| JP2010083896A5 (hr) | ||
| Zhang et al. | Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors | |
| JP2000502687A (ja) | メタロペプチダーゼ阻害活性を有するチオール誘導体 | |
| RU2009122504A (ru) | Гетероциклические производные в качестве ингибиторов белка сетр | |
| AR075988A1 (es) | Compuesto de piridiloxi - pirrolidina inhibidor de recaptacion de serotonina y norepinefrina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de dolor cronico | |
| KR20080020638A (ko) | β-아드레날린 수용체 키나제 1의 억제제로서의피라졸로피리딘 유도체 | |
| Goulet et al. | Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization |